|Cancer||Cell death||Cell cycle||Cytoskeleton||Exo/endocytosis||Differentiation||Division||Organelles||Signalling||Stem cells||Trafficking|
Cell Biology International (2009) 33, 548554 (Printed in Great Britain)
Induction of apoptosis by Hax-1 siRNA in melanoma cells
Wen‑Bin Lia, Jie Fenga*, Song‑Mei Genga, Peng‑Yu Zhangb, Xiao‑Ning Yana, Gang Hua, Cai‑Qing Zhanga and Bing‑Jun Shia
aDepartment of Dermatology, The Second Affiliated Hospital, Xi'an Jiaotong University School of Medicine, The West Five Road, 157#, Xi'an, Shaanxi 710004, PR China
bDepartment of Clinical Hematology, The Second Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710004, PR China
HS1-associated protein X-1 (Hax-1) is a novel intracellular protein and recent studies suggested that it is an anti-apoptotic factor in different tumors. Hax-1 expression was upregulated in various metastatic tumors and cancer cell lines, including melanoma. To understand the role of Hax-1 in melanoma development and progression, we constructed Hax-1 short interfering RNA (siRNA) expression vectors to downregulate Hax-1 expression in a human melanoma A375 cell line. One of the two Hax-1 RNA interference (RNAi) constructs significantly reduced melanoma cell viability, which was due to induction of apoptosis in A375 cells. Molecularly, the induced apoptosis through downregulation of Hax-1 expression was mediated by activation of caspase-3 and poly-ADP-ribose polymerase (PARP) enzymatic activity in A375 cells. The data indicate that Hax-1 plays a role in suppression of apoptosis and promotion of melanoma cell growth, suggesting that this Hax-1 siRNA has a therapeutic indication in control of melanoma.
Keywords: Hax-1, RNAi, Apoptosis, Melanoma.
*Corresponding author. Tel./fax: +86 29 87678312.
Malignant melanoma is a devastating type of cancer because of its high metastatic potential. Its incidence has been increasing on average by 7% a year worldwide. Metastatic disease is the major cause of death among melanoma patients because at the time of diagnosis a large number of them already have metastasis. The long-term survival for patients with metastatic melanoma is only 5% (Brown and Nelson, 1999). Currently, clinical therapy for control of melanoma includes surgery, radiation, and polychemotherapy; however, many metastatic melanomas are typically resistant to radiation and treatments with currently available cytotoxic chemotherapeutic agents have not been effective (Margolin et al., 1998; Tang et al., 1998). Therefore, emphasis is placed on early detection and novel targeted therapeutic regimens are also being investigated. One of them is to induce melanoma cells to undergo apoptosis because some melanomas maintain an anti-apoptotic phenotype. Published studies demonstrated that a number of anti-apoptotic proteins, such as bcl-2, Bcl-xL, and X-linked inhibitor of apoptosis (XIAP), are overexpressed in melanoma and may confer resistance to chemotherapy (Tang et al., 1998; Bush and Li, 2003).
HS1-associated protein X-1 (Hax-1) is a novel intracellular protein, which is localized mainly in mitochondria, but also in endoplasmic reticulum and nuclear envelope in the cells (Suzuki et al., 1997). Several studies have revealed that Hax-1 interacts with viral proteins and plays a role in promoting virus-infected cells survival by inhibition of apoptosis (Dufva et al., 2001; Sharp et al., 2002; Yedavalli et al., 2005). A recent study showed that Hax-1, a substrate of caspase-3, inhibits the apoptotic process by inhibiting caspase-3 activity (Lee et al., 2008). Moreover, in cardiac myocytes and HaCaT cells, Hax-1 could protect them from apoptosis through a caspase-dependent pathway (Mirmohammadsadegh et al., 2003; Han et al., 2006). Other studies have shown that Hax-1 expression was upregulated in different types of tumors, including melanoma (Velculescu et al., 1995; Jiang et al., 2003; Mirmohammadsadegh et al., 2003; Yamaguchi et al., 2005). However, the importance of the Hax-1 gene in melanoma is unknown. Therefore, we have studied the role of Hax-1 in melanoma by using an siRNA technique, which is a promising new tool to evaluate gene functions in cells and has potential applications for therapy (Almeida and Allshire, 2005; Aagaard and Rossi, 2007).
2 Materials and methods
2.1 Cell culture
Human melanoma A375 cells and HaCaT (spontaneously immortalized human epidermal keratinocyte) cells were obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Hang Zhou, Sijiqing, China) at 37
2.2 Western blotting
A375 and HaCaT cells were seeded in 25
2.3 Construction of Hax-1 siRNA expression vectors
The Hax-1 cDNA sequences (NM_006118) were obtained from GeneBank and Hax-1 siRNA sequences were selected by using an siRNA selection program from Whitehead Institute for Biomedical Research (Cambridge, MA, http://jura.wi.mit.edu/bioc/siRNA). The oligonucleotides were synthesized and purified by Shanghai Biological Engineering Company (Shanghai, China). The oligonucleotides were annealed and cloned into the linearized pSUPER/puro vector (oligoengine, Seattle, WA), which contains a polymerase-III H1-RNA gene promoter. The Hax-1 siRNA constructs were amplified and verified by DNA sequencing and were named pSUPER-siH1 and pSUPER-siH2, respectively. The scrambled control plasmid (pSUPER-C) was a circular plasmid encoding an shRNA that did not match any sequence found in the human genome databases. The sequences used to construct the vectors are as follows: Hax-1-siRNA1 (targeting Hax-1 nucleotide positions at 924–942), 5′-GATCCCCTCACCAAGACCTCCAGCCCTTCAAGAGAGGGCTGGAGGTCTTGGTGATTTTTA-3′ and Hax-1-siRNA2 (nucleotide positions at 310–328), 5′-GATCCCCGGTTCCATAGTCCTCAGCATTCAAGAGATGCTGAGGACTATGGAACCTTTTTA-3′. The scrambled sequence used as a control vector was 5′-GATCCCCAGAGCGAGAGCCTCTATATTTCAAGAGAATATAGAGGCTCTCGCTCTTTTTTA-3′.
2.4 Gene transfection
A375 cells were seeded in 6-well plates at a density of 1
2.5 Quantitative real-time reverse transcription-polymerase chain reaction (Q-RT-PCR)
RNA isolation and Q-RT-PCR analysis were performed as described previously (Gorreta et al., 2005). Briefly, total RNA from the cells was extracted using Trizol (Invitrogen) and cDNAs were synthesized in 20
2.6 Methyl thiazolyl tetrazolium (MTT) assay
Cells were seeded at 3
2.7 Flow cytometric analysis of cell cycle and apoptosis
Cells were seeded into a 6-well culture plate and transfected with Hax-1 siRNA vectors using Lipofectamine 2000. After two days post-transfection, the cells were washed twice with ice-cold PBS and fixed in 70% ice-cold ethanol for 4
2.8 Hoechst 33258 staining
A Hoechst 33258 cell apoptosis staining kit (Beyotime, Nanjing, China) was used to confirm morphological changes in the nuclei. The transfected cells were seeded onto sterile glass coverslips placed in 6-well plates and incubated for 48
2.9 Caspase-3 activity assay
Caspase-3 enzymatic activity was determined using a caspase activity kit (Clontech, Mountain View, CA) according to the manufacturer's protocol. Briefly, cell lysates were prepared and caspase-3 substrate (Ac-DVED-pNA) was added to cell lysates. The mixtures were incubated at 37
2.10 Statistical analysis
All numeric data were presented as mean
3.1 Downregulation of Hax-1 expression by Hax-1 siRNA
We first assessed Hax-1 expression in the melanoma cell line A375 by using western blotting analysis. Compared to positive control (Mirmohammadsadegh et al., 2003), A375 cells expressed very high levels of Hax-1 protein (Fig. 1). We constructed two Hax-1 siRNA expression vectors. After transfection of these vectors into A375 cells, Q-RT-PCR and Western blotting analyses showed that one of these Hax-1 siRNA vectors successfully downregulated Hax-1 expression in A375 cells (Fig. 2). However, another Hax-1 siRNA, namely pSUPER-siH2 and scrambled control vector had no effects on suppression of Hax-1 expression (Fig. 2).
Western blotting analysis of Hax-1 expression in A375 cells. Both HaCaT (a positive control) and A375 cells were grown in monolayer and total cellular protein was extracted and subjected to Western blotting analysis.
Downregulation of Hax-1 expression using Hax-1 siRNA. Two Hax-1 siRNAs were constructed and transfected into A375 cells. Quantitative real-time PCR (A) and Western blotting (B) analysis were used to detect Hax-1 mRNA and protein expression, respectively. (A) Each bar represents mean
3.2 Reduced cell viability after downregulation of Hax-1 expression due to induction of apoptosis
To explore the role of Hax-1 in melanoma, we first determined cell viability after Hax-1 siRNA transfection by using MTT assay. The viability of A375 cells after pSUPER-siH1 transfection was significantly reduced (Fig. 3). To determine the causes of the reduced cell viability after downregulation of Hax-1 expression, a flow cytometry analysis of cell cycle distribution was carried out. Downregulation of Hax-1 expression had a minimal effect on cycle distributions, including G1, S and G2/M phases in A375 cells (data not shown). On the other hand, after pSUPER-siH1 transfection the population of sub-G1 phase increased (a hypodiploid DNA peak), suggesting that downregulation of Hax-1 induced apoptosis in A375 cells. Thereafter, we measured the apoptosis levels in the cells. The pSUPER-siH1-transfected A375 cells had an increased apoptosis rate of 83.6%, as compared with the cells transfected with pSUPER-C and the parental A375 cells (Fig. 4). Furthermore, apoptosis induced by the downregulation of Hax-1 in A375 cells following transfection with pSUPER-siH1 showed apoptotic morphology features (using light microscopy), such as cell shrinkage, chromatin compaction, condensation of cytoplasm, and detachment of the cellular monolayer. Hoechst 33258 staining showed that there were significant morphological changes in nuclear chromatin. In the control cultures, the nuclei were stained a less bright blue and the color was homogeneous. However, condensed chromatin could be observed in cells transfected with pSUPER-siH1 and some formed apoptotic bodies (Fig. 5).
MTT assay. Cell viability was detected using MTT assay after Hax-1 siRNA transfection (see details in
Flow cytometric assay. Apoptosis rate was detected using Annexin V/FITC and propidium iodide (PI) staining followed by flow cytometric analysis. The cell were grown and transfected with Hax-1 siRNA or control siRNA and the cells were subjected to Annexin V and PI staining (see details in method section) and flow cytometric analysis.
Hoechst 33258 staining. The cells were grown and transfected with Hax-1 siRNA or control siRNA. After that, the cells were stained with Hoechst 33258 solution and reviewed under a microscope. A, A375 cells without any transfection; B, pSUPER-C-transfected A375 cells; and C, pSUPER-siH1-transfected A375 cells.
3.3 Induced apoptosis after downregulation of Hax-1 expression via activation of caspase-3 and PARP activity
Both caspase-3 and PARP upregulation occur molecularly at the end stages of apoptosis cascades, which are excellent markers for apoptosis. We detected their activation after Hax-1 siRNA transfection in A375 cells. Western blotting data clearly showed that pSUPER-siH1 transfectants increased the active forms of caspase-3 and PARP expression compared to the controls (Fig. 6A). The caspase-3 enzymatic activity was also measured (Fig. 6B); caspase-3 enzymatic activity in the pSUPER-siH1-transfected cells increased >2-fold as compared to control cells and the increased caspase-3 activity was blocked by the inhibitor DEVD-fmk. Moreover, UV radiation (2.4
Detection of caspase-3 and PARP activation. A, Western blotting analysis. The cells were grown and transfected with Hax-1 siRNA or control vector. After that, total cellular protein was extracted and subjected to Western blotting analysis. Lane 1, parental A375 cells; lane 2, pSUPER-C, and lane 3, pSUPER-siH1. B, ELISA assay. The cells were grown and transfected with Hax-1 siRNA or control vector and then exposed to UV for 5
Hax-1 siRNA expression vector was used to downregulate Hax-1 expression in melanoma cells. One of the Hax-1 siRNA constructs significantly reduced the melanoma cell viability and induced them to undergo apoptosis. Molecularly, activation of caspase-3 and PARP enzymatic activity were responsible for apoptosis in the A375 cells. The data suggest that Hax-1 plays a role in suppression of apoptosis and promotion of melanoma cell growth, which indicates that the Hax-1 siRNA may have a therapeutic clinical indication, but further study is warranted to determine whether this Hax-1 siRNA has the potential to control melanoma.
Hax-1, a novel 35
Apoptosis is an important mechanism regulating cell survival and normal homeostasis in the human body. Altered apoptosis processes will promote carcinogenesis and increase resistance to chemotherapy in cancer patients (Kaufmann and Gores, 2000; Schmitt, 2003). Several studies have shown that Hax-1 is upregulated in some metastatic tumors and tumor cell lines, including melanoma cell lines (Velculescu et al., 1995; Jiang et al., 2003; Mirmohammadsadegh et al., 2003; Yamaguchi et al., 2005). We have focused on Hax-1 due to its noted anti-apoptosis effect. Hax-1 protein was overexpressed in A375 cells compared to HaCaT cells. We constructed the two Hax-1 siRNA vectors to downregulate Hax-1 expression in A375 cells and showed that transfection of pSUPER-siH1 effectively reduced Hax-1 expression and induced apoptosis in A375 cells. This finding may show that Hax-1 siRNA might help control melanoma because RNAi techniques provide a rapid and versatile method that inactivates expression of the target genes (Brummelkamp et al., 2002; Sun et al., 2007).
Apoptosis is characterized by cell shrinkage and rounding, membrane blebbing, chromatin condensation and breakdown, as well as caspase activation (Ziegler and Groscurth, 2004; Rello et al., 2005). Cysteine aspartases (caspases), a family of proteases, are known to play a key role in signal transduction cascades that culminate in apoptosis. Among all of the caspases, caspase-3 is one of the key executioners of apoptosis and results in DNA fragmentation and cell death (Porter and Janicke, 1999; Slee et al., 2001). Moreover, the activation of caspase-3 results in cleavage of the DNA-repair enzyme PARP and the latter is also a land marker during apoptosis induction (Kuida et al., 1996; Cohen, 1997). In the present study, Hax-1 downregulation led to an increase in the expression of the active form of caspase-3 and PARP proteins. The caspase-3 activity induced by Hax-1 downregulation was inhibited by a caspase-3 inhibitor, indicating that Hax-1-inhibited apoptosis required the suppression of caspase-3 activation. A recent study showed that Hax-1 is a substrate of caspase-3 and therefore inhibits the apoptotic process (Lee et al., 2008). Our results confirmed that Hax-1 inhibits apoptosis through a caspase-dependent pathway.
Hax-1 can also promote survival of virus-infected cells (Kawaguchi et al., 2000; Sharp et al., 2002; Cilenti et al., 2004; Yedavalli et al., 2005) and another study showed that overexpression of Hax-1 increases cell viability under H
The authors wish to thank Medjaden Biomedical Services for their critical review of this manuscript. This project was supported by grants from the National Natural Science Foundation of China (No. 30600536).
Cilenti L, Soundarapandian, MM, Kyriazis, GA, Stratico, V, Singh, S, Gupta, S. Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J Biol Chem 2004:279:50295-301
Gorreta F, Runfola, TP, VanMeter, AJ, Barzaghi, D, Chandhoke, V, Del Giacco, L. Identification of thioredoxin reductase 1-regulated genes using small interference RNA and cDNA microarray. Cancer Biol Ther 2005:4:1079-88
Han Y, Chen, YS, Liu, Z, Bodyak, N, Rigor, D, Bisping, E. Overexpression of HAX-1 protects cardiac myocytes from apoptosis through caspase-9 inhibition. Circ Res 2006:99:415-23
Jiang Y, Zhang, W, Kondo, K, Klco, JM, St Martin, TB, Dufault, MR. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 2003:1:453-62
Kawaguchi Y, Nakajima, K, Igarashi, M, Morita, T, Tanaka, M, Suzuki, M. Interaction of Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) with HS1-associated protein X-1: implication of cytoplasmic function of EBNA-LP. J Virol 2000:74:10104-11
Margolin KA, Liu, PY, Flaherty, LE, Sosman, JA, Walker, MJ, Smith, JW. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 1998:16:664-9
Mirmohammadsadegh A, Tartler, U, Michel, G, Baer, A, Walz, M, Wolf, R. HAX-1, identified by differential display reverse transcription polymerase chain reaction, is overexpressed in lesional psoriasis. J Invest Dermatol 2003:120:1045-51
Rello S, Stockert, JC, Moreno, V, Gamez, A, Pacheco, M, Juarranz, A. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis 2005:10:201-8
Sharp TV, Wang, HW, Koumi, A, Hollyman, D, Endo, Y, Ye, H. K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol 2002:76:802-16
Slee EA, Adrain, C, Martin, SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001:276:7320-6
Sun Y, Yi, H, Zhang, PF, Li, MY, Li, C, Li, F. Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett 2007:581:131-9
Suzuki Y, Demoliere, C, Kitamura, D, Takeshita, H, Deuschle, U, Watanabe, T. HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J Immunol 1997:158:2736-44
Vafiadaki E, Sanoudou, D, Arvanitis, DA, Catino, DH, Kranias, EG, Kontrogianni-Konstantopoulos, A. Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function. J Mol Biol 2007:367:65-79
Yedavalli VS, Shih, HM, Chiang, YP, Lu, CY, Chang, LY, Chen, MY. Human immunodeficiency virus type 1 Vpr interacts with antiapoptotic mitochondrial protein HAX-1. J Virol 2005:79:13735-46
Received 13 November 2008/19 January 2009; accepted 20 February 2009doi:10.1016/j.cellbi.2009.02.005